

Ref. No: 268060921
From: Commercial
Date: 06/09/21
Subject: Biologic and biosimilar products within Rheumatology

REQUEST

Wilmington Healthcare is analysing the usage of biologic and biosimilar products within Rheumatology. It would be really helpful if you could provide the numbers of patients treated by the **rheumatology** department (for any condition) in the last 3 months with the following drugs:

- Abatacept [Orencia]
- Adalimumab [Humira]
- Adalimumab Biosimilars
- Apremilast [Otezla]
- Baricitinib [Olumiant]
- Certolizumab [Cimzia]
- Etanercept [Enbrel]
- Etanercept Biosimilars
- Filgotinib [Jyseleca]
- Golimumab [Simponi]
- Guselkumab [Tremfya]
- Infliximab [Remicade]
- Infliximab Biosimilars
- Ixekizumab [Taltz]
- Risankizumab [Skyrizi]
- Rituximab [MabThera]
- Rituximab Biosimilars
- Sarilumab [Kevzara]
- Secukinumab [Cosentyx]
- Tocilizumab [Ro Actemra]
- Tofacitinib [Xeljanz]
- Upadacitinib [Rinvoq]
- Ustekinumab [Stelara]

RESPONSE

Pharmacy Issue Data 1st June 2021 – 31st August 2021

	Number of Patients
Abatacept [Orencia]	33
Adalimumab [Humira]	38
Adalimumab Biosimilars	134
Apremilast [Otezla]	*
Baricitinib [Olumiant]	83
Certolizumab [Cimzia]	16
Etanercept [Enbrel]	41
Etanercept Biosimilars	91
Filgotinib [Jyseleca]	*
Golimumab [Simponi]	31
Guselkumab [Tremfya]	0
Infliximab [Remicade]	*
Infliximab Biosimilars	11
Ixekizumab [Taltz]	0
Risankizumab [Skyrizi]	0
Rituximab [MabThera]	0
Rituximab Biosimilars	19
Sarilumab [Kevzara]	0
Secukinumab [Cosentyx]	26
Tocilizumab [Ro Actemra]	40
Tofacitinib [Xeljanz]	21
Upadacitinib [Rinvoq]	0
Ustekinumab [Stelara]	*

* **Please note:** We are unable to provide precise figures when those figures refer to individuals in volumes of 5 or less due to the risk that individuals will be re-identified, as we are required to protect their identity under the General Data Protection Regulations & Data Protection Act 2018. In such circumstances sections 40(2) and (3) of the Freedom of Information Act apply. In this case, our view is that disclosure would breach the first data protection principle. This states that personal data should be processed “lawfully, fairly and in a transparent manner”. It is the lawful aspect of this principle which, in our view, would be breached by disclosure. In such circumstances section 40 confers an absolute exemption on disclosure.